SEC Company Response from Clinuvel Pharmaceuticals (CUVL) — Jul 9, 2026
Clinuvel Pharmaceuticals Ltd
Date: July 9, 2026 · CIK: 0001290877 · Accession: 0001493152-26-032648
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-43353
Letter
Clinuvel Pharmaceuticals Limited
July 9, 2026
Via EDGAR
Division of Corporation Finance
Office of Life Sciences
U.S. Securities and Exchange Commission
F Street, NE
Washington, D.C., 20549
Attention:
Vanessa Robertson
Bonnie Baynes Joe McCann Lauren Sprague Hamill
Re: Clinuvel Pharmaceuticals Limited
Registration Statement on Form 20-F
File No. 001-43353 Withdrawal of Acceleration Request
Ladies and Gentlemen:
Reference is made to our letter, filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on July 6, 2026, in which we requested the acceleration of the effective date of the above-captioned Registration Statement for July 8, 2026, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter, in accordance with Rule 12d1-2 promulgated under the Securities Exchange Act of 1934, as amended. Clinuvel Pharmaceuticals Limited is no longer requesting that such Registration Statement be declared effective at such date and time, and we hereby formally withdraw our request for acceleration of the effective date of the above-captioned Registration Statement.
Very truly yours,
Clinuvel Pharmaceuticals Limited
Show Raw Text
CORRESP 1 filename1.htm Clinuvel Pharmaceuticals Limited July 9, 2026 Via EDGAR Division of Corporation Finance Office of Life Sciences U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C., 20549 Attention: Vanessa Robertson Bonnie Baynes Joe McCann Lauren Sprague Hamill Re: Clinuvel Pharmaceuticals Limited Registration Statement on Form 20-F File No. 001-43353 Withdrawal of Acceleration Request Ladies and Gentlemen: Reference is made to our letter, filed as correspondence with the U.S. Securities and Exchange Commission via EDGAR on July 6, 2026, in which we requested the acceleration of the effective date of the above-captioned Registration Statement for July 8, 2026, at 4:00 p.m. Eastern Time, or as soon as practicable thereafter, in accordance with Rule 12d1-2 promulgated under the Securities Exchange Act of 1934, as amended. Clinuvel Pharmaceuticals Limited is no longer requesting that such Registration Statement be declared effective at such date and time, and we hereby formally withdraw our request for acceleration of the effective date of the above-captioned Registration Statement. Very truly yours, Clinuvel Pharmaceuticals Limited By: /s/ Philippe Wolgen Name: Philippe Wolgen Title: Managing Director and Chief Executive Officer